Spectral observations of X Persei: Connection between H-alpha and X-ray emission

We present spectroscopic observations of the Be/X-ray binary X Per obtained during the period 1999 - 2018. Using new and published data, we found that during "disc-rise" the expansion velocity of the circumstellar disc is 0.4 - 0.7 km/s. Our results suggest that the disc radius in recent decades show evidence of resonant truncation of the disc by resonances 10:1, 3:1, and 2:1, while the maximum disc size is larger than the Roche lobe of the primary and smaller than the closest approach of the neutron star. We find correlation between equivalent width of H-alpha emission line ($W\alpha$) and the X-ray flux, which is visible when $15 \: \AA \: < W\alpha \le 40 \: \AA$. The correlation is probably due to wind Roche lobe overflow.Comment: Accepted for publication in Astronomy & Astrophysic

Pre-outburst signal in the light curves of the recurrent novae RS Oph and T CrB

Pre-outburst signal (a decrease of the optical brightness) just before the outburst is clearly detected in the observations of the T CrB obtained before and during the 1946 outburst. A similar decrease is also visible in the light curve of RS Oph during the 2021 outburst. We suppose that this is due to formation of a thick, dense envelope around the white dwarf, and we estimate its size (1000 - 2000 km), mass (5.10$^{-8}$ - 6.10$^{-7}$ M$_\odot$) and average density (5 - 16 g cm$^{-3}$).Comment: preliminary versio

The hidden symbiotic star SU Lyn-detection of flickering in U band

We report photometric observations of the hidden symbiotic star SU Lyn in the optical bands. In four nights we detect a weak flickering in U band with amplitude of about 0.05 magnitudes. No intranight variations are found in B, V, g’ and r’ bands. This is one more indication that the secondary component is a white dwarf accreting at a low accretion rate Ẇe also searched for intranight variability of a dozen related objects-RR Boo, RT Boo, AM Cyg, AG Peg, BF Cyg, NQ Gem, StHa190, V627 Cas, XX Oph, FS Cet and Y Gem-however no variability above the observational errors is detected

Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF)

&lt;p&gt;Aims: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.&lt;/p&gt; &lt;p&gt;Methods and results: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate &#60;60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.&lt;/p&gt; &lt;p&gt;Conclusion: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.&lt;/p&gt

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe